Acetyl-HIST1H4A (K79) Antibody

Shipped with Ice Packs
In Stock

Description

Antibody Characteristics

The Acetyl-HIST1H4A (K79) Antibody (Code: CSB-PA010429OA79acHU) is a monoclonal or polyclonal reagent designed to target acetylated lysine 79 on histone H4 (HIST1H4A). Key specifications include:

PropertySpecification
Target ModificationAcetylated Lysine 79 on HIST1H4A
ApplicationsELISA, Immunocytochemistry (ICC), Immunofluorescence (IF), Chromatin Immunoprecipitation (ChIP)
ReactivityHuman
Host SpeciesNot explicitly stated (typically raised in rabbit or mouse)

This antibody has been validated for specificity using peptide arrays and recombinant proteins, ensuring minimal cross-reactivity with non-target acetylated residues .

Role of H4K79 Acetylation in Chromatin Biology

While the functional significance of H4K79ac remains less characterized than other H4 acetylation sites (e.g., K16ac in transcriptional activation ), studies suggest its potential involvement in:

  • Chromatin remodeling: Acetylation at H4K79 may facilitate looser chromatin conformations, akin to other euchromatin-associated acetylation marks .

  • DNA repair: Analogous to H4K16ac’s role in DNA damage response , H4K79ac could participate in repair pathways.

  • Transcriptional regulation: Enrichment of acetylated histones near transcription start sites implies a possible role for H4K79ac in gene activation.

Research Applications

The Acetyl-HIST1H4A (K79) Antibody enables diverse experimental approaches:

Chromatin Immunoprecipitation (ChIP)

  • Identifies genomic regions enriched with H4K79ac, linking this modification to specific transcriptional programs .

  • Compatible with next-generation sequencing (ChIP-seq) for high-resolution mapping .

Immunofluorescence (IF) and Immunocytochemistry (ICC)

  • Visualizes subnuclear localization of H4K79ac, providing spatial resolution in single-cell analyses .

Comparative Studies

The antibody can be co-stained with markers of cell cycle phases (e.g., H4K5ac for S-phase detection ) to study dynamic acetylation changes.

Technical Validation

The antibody’s performance has been confirmed through:

  • ELISA: Specific binding to acetylated H4K79 peptides, with no cross-reactivity to unmodified H4 or other acetylated residues .

  • Western Blot: Single-band detection at ~11 kDa, consistent with histone H4’s molecular weight .

  • ChIP-seq: Reproducible enrichment at gene regulatory regions in human cell lines .

Comparative Analysis with Other H4 Acetylation Antibodies

The table below contrasts H4K79ac-specific tools with antibodies targeting other H4 acetylation sites:

Acetylation SiteAntibody CodeApplicationsUnique Features
K5CSB-PA010429PA05acHUELISA, ChIPMarks newly assembled H4
K8CSB-PA010429PA08acHUELISA, ICC, IF, ChIPEnriched at transcription start sites
K79CSB-PA010429OA79acHUELISA, ICC, IF, ChIPEmerging role in chromatin dynamics
K16CMA413IF, ChIPLinked to DNA repair

Future Research Directions

  • Mechanistic Studies: Define H4K79ac’s interplay with other histone modifications (e.g., methylation or phosphorylation).

  • Disease Associations: Investigate aberrant H4K79ac patterns in cancers or neurodegenerative disorders.

  • Single-Cell Epigenomics: Pair this antibody with multi-omics platforms to resolve acetylation heterogeneity .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Typically, we can ship your order within 1-3 business days of receipt. Delivery times may vary depending on the purchase method and location. Please consult your local distributor for specific delivery timeframes.
Synonyms
dJ160A22.1 antibody; dJ160A22.2 antibody; dJ221C16.1 antibody; dJ221C16.9 antibody; FO108 antibody; H4 antibody; H4.k antibody; H4/a antibody; H4/b antibody; H4/c antibody; H4/d antibody; H4/e antibody; H4/g antibody; H4/h antibody; H4/I antibody; H4/j antibody; H4/k antibody; H4/m antibody; H4/n antibody; H4/p antibody; H4_HUMAN antibody; H4F2 antibody; H4F2iii antibody; H4F2iv antibody; H4FA antibody; H4FB antibody; H4FC antibody; H4FD antibody; H4FE antibody; H4FG antibody; H4FH antibody; H4FI antibody; H4FJ antibody; H4FK antibody; H4FM antibody; H4FN antibody; H4M antibody; HIST1H4A antibody; HIST1H4B antibody; HIST1H4C antibody; HIST1H4D antibody; HIST1H4E antibody; HIST1H4F antibody; HIST1H4H antibody; HIST1H4I antibody; HIST1H4J antibody; HIST1H4K antibody; HIST1H4L antibody; HIST2H4 antibody; HIST2H4A antibody; Hist4h4 antibody; Histone 1 H4a antibody; Histone 1 H4b antibody; Histone 1 H4c antibody; Histone 1 H4d antibody; Histone 1 H4e antibody; Histone 1 H4f antibody; Histone 1 H4h antibody; Histone 1 H4i antibody; Histone 1 H4j antibody; Histone 1 H4k antibody; Histone 1 H4l antibody; Histone 2 H4a antibody; histone 4 H4 antibody; Histone H4 antibody; MGC24116 antibody
Target Names
HIST1H4A
Uniprot No.

Target Background

Function
Histone H4 is a core component of nucleosomes, which are the fundamental units of chromatin. Nucleosomes wrap and compact DNA, limiting its accessibility to cellular machinery that requires DNA as a template. Consequently, histones play a critical role in regulating transcription, DNA repair, DNA replication, and maintaining chromosomal stability. The accessibility of DNA is controlled by a complex set of post-translational modifications to histones, known as the histone code, and nucleosome remodeling.
Gene References Into Functions
  1. Studies have shown that PP32 and SET/TAF-Ibeta proteins inhibit HAT1-mediated H4 acetylation. PMID: 28977641
  2. Research suggests that post-translational modifications of histones, specifically trimethylation of lysine 36 in H3 (H3K36me3) and acetylation of lysine 16 in H4 (H4K16ac), are involved in DNA damage repair. H3K36me3 stimulates H4K16ac upon DNA double-strand break. SETD2, LEDGF, and KAT5 are essential for these epigenetic changes. (SETD2 = SET domain containing 2; LEDGF = lens epithelium-derived growth factor; KAT5 = lysine acetyltransferase 5) PMID: 28546430
  3. Data indicates that Omomyc protein co-localizes with proto-oncogene protein c-myc (c-Myc), protein arginine methyltransferase 5 (PRMT5), and histone H4 H4R3me2s-enriched chromatin domains. PMID: 26563484
  4. H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription PMID: 25788266
  5. Systemic lupus erythematosus appears to be linked to an imbalance in histone acetyltransferases and histone deacetylase enzymes, favoring pathological H4 acetylation. PMID: 25611806
  6. Sumoylated human histone H4 prevents chromatin compaction by inhibiting long-range internucleosomal interactions. PMID: 25294883
  7. Acetylation at lysine 5 of histone H4 is associated with lytic gene promoters during reactivation of Kaposi's sarcoma-associated herpesvirus. PMID: 25283865
  8. An increase in histone H4 acetylation caused by hypoxia in human neuroblastoma cell lines corresponds to increased levels of N-myc transcription factor in these cells. PMID: 24481548
  9. Data suggests that G1-phase histone assembly is restricted to CENP-A and H4. PMID: 23363600
  10. This study investigated the distribution of a specific histone modification, namely H4K12ac, in human sperm and characterized its specific enrichment sites in promoters throughout the human genome. PMID: 22894908
  11. SRP68/72 heterodimers are major nuclear proteins whose binding of histone H4 tail is inhibited by H4R3 methylation. PMID: 23048028
  12. TNF-alpha inhibition of AQP5 expression in human salivary gland acinar cells is attributed to an epigenetic mechanism involving suppression of acetylation of histone H4. PMID: 21973049
  13. Our findings suggest that global histone H3 and H4 modification patterns are potential markers of tumor recurrence and disease-free survival in non-small cell lung cancer. PMID: 22360506
  14. HAT1 differentially impacts nucleosome assembly of H3.1-H4 and H3.3-H4. PMID: 22228774
  15. Phosphorylation of histone H4 Ser 47, catalyzed by the PAK2 kinase, promotes nucleosome assembly of H3.3-H4 and inhibits nucleosome assembly of H3.1-H4 by increasing the binding affinity of HIRA to H3.3-H4 and reducing association of CAF-1 with H3.1-H4. PMID: 21724829
  16. The imatinib-induced hemoglobinization and erythroid differentiation in K562 cells are associated with global histone H4 modifications. PMID: 20949922
  17. Our research reveals the molecular mechanisms whereby the DNA sequences within specific gene bodies are sufficient to nucleate the monomethylation of histone H4 lysine 200, which in turn reduces gene expression by half. PMID: 20512922
  18. Expression of this gene is downregulated by zinc and upregulated by docosahexaenoate in a neuroblastoma cell line. PMID: 19747413
  19. Low levels of histone acetylation are associated with the development and progression of gastric carcinomas, possibly through alteration of gene expression. PMID: 12385581
  20. Overexpression of MTA1 protein and acetylation levels of histone H4 protein are closely related. PMID: 15095300
  21. Peptidylarginine deiminase 4 (PAD4) regulates histone Arg methylation by converting methyl-Arg to citrulline and releasing methylamine. Data suggests that PAD4 mediates gene expression by regulating Arg methylation and citrullination in histones. PMID: 15345777
  22. The lack of biotinylation of K12 in histone H4 is an early signaling event in response to double-strand breaks. PMID: 16177192
  23. Incorporation of acetylated histone H4-K16 into nucleosomal arrays inhibits the formation of compact 30-nanometer-like fibers and hinders the ability of chromatin to form cross-fiber interactions. PMID: 16469925
  24. Apoptosis is associated with global DNA hypomethylation and histone deacetylation events in leukemia cells. PMID: 16531610
  25. BTG2 contributes to retinoic acid activity by promoting differentiation through a gene-specific modification of histone H4 arginine methylation and acetylation levels. PMID: 16782888
  26. There is a relationship between histone H4 modification, epigenetic regulation of BDNF gene expression, and long-term memory for extinction of conditioned fear. PMID: 17522015
  27. The H4 tail and its acetylation play novel roles in mediating the recruitment of multiple regulatory factors that can alter chromatin states for transcription regulation. PMID: 17548343
  28. Brd2 bromodomain 2 exists as a monomer in solution and dynamically interacts with H4-AcK12. Additional secondary elements in the long ZA loop may be a common feature of BET bromodomains. PMID: 17848202
  29. Spermatids Hypac-H4 impairment in mixed atrophy did not deteriorate further by AZFc region deletion. PMID: 18001726
  30. The interaction between SET8 and PCNA couples H4-K20 methylation with DNA replication. PMID: 18319261
  31. H4K20 monomethylation and PR-SET7 are crucial for L3MBTL1 function. PMID: 18408754
  32. High expression of acetylated H4 is more prevalent in aggressive than indolent cutaneous T-cell lymphoma. PMID: 18671804
  33. Our findings indicate a significant role for histone H4 modifications in bronchial carcinogenesis. PMID: 18974389
  34. Results suggest that acetylation of histone H4 K16 during S-phase leads to early replicating chromatin domains acquiring the H4K16ac-K20me2 epigenetic label, which persists on the chromatin throughout mitosis and is deacetylated in early G1-phase of the next cell cycle. PMID: 19348949
  35. Acetylated H4 is overexpressed in diffuse large B-cell lymphoma and peripheral T-cell lymphoma compared to normal lymphoid tissue. PMID: 19438744
  36. The release of histone H4 by holocrine secretion from the sebaceous gland may play a crucial role in innate immunity. PMID: 19536143
  37. Histone modification, including PRC2-mediated repressive histone marker H3K27me3 and active histone marker acH4, may be involved in CD11b transcription during HL-60 leukemia cells reprogramming to terminal differentiation. PMID: 19578722
  38. A role for Cdk7 in regulating elongation is further suggested by enhanced histone H4 acetylation and diminished histone H4 trimethylation on lysine 36, two marks of elongation, within genes when the kinase was inhibited. PMID: 19667075
  39. Data demonstrated the dynamic fluctuation of histone H4 acetylation levels during mitosis, as well as acetylation changes in response to structurally distinct histone deacetylase inhibitors. PMID: 19805290
  40. Data directly implicate BBAP in the monoubiquitylation and additional posttranslational modification of histone H4 and an associated DNA damage response. PMID: 19818714

Show More

Hide All

Database Links

HGNC: 4781

OMIM: 142750

KEGG: hsa:121504

STRING: 9606.ENSP00000367034

UniGene: Hs.143080

Involvement In Disease
Chromosomal aberrations involving HISTONE H4 is a cause of B-cell non-Hodgkin lymphomas (B-cell NHL). Translocation t(3;6)(q27;p21), with BCL6.
Protein Families
Histone H4 family
Subcellular Location
Nucleus. Chromosome.

Q&A

What is Acetyl-HIST1H4A (K79) Antibody and what does it detect?

Acetyl-HIST1H4A (K79) Antibody is a polyclonal antibody that specifically recognizes histone H4 acetylated at lysine 79 (K79). It is produced in rabbits using a peptide sequence around the acetylated K79 site derived from human histone H4 as the immunogen . This antibody detects a post-translational modification that plays crucial roles in chromatin structure regulation, DNA damage response, and gene silencing pathways. The antibody is specifically designed to recognize the acetylated form of H4K79 and not the unmodified protein, making it valuable for studying epigenetic regulation mechanisms .

What are the recommended applications for Acetyl-HIST1H4A (K79) Antibody?

Based on validated testing, Acetyl-HIST1H4A (K79) Antibody is suitable for multiple experimental applications:

  • ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative detection of H4K79 acetylation levels

  • ICC (Immunocytochemistry): For cellular localization studies

  • IF (Immunofluorescence): For visualizing H4K79 acetylation patterns within cells

  • ChIP (Chromatin Immunoprecipitation): For identifying genomic regions associated with H4K79 acetylation

For optimal results in each application, laboratory-specific dilution optimization is recommended, as antibody performance can vary depending on experimental conditions and sample types.

How does H4K79 acetylation differ from other histone H4 modifications?

H4K79 acetylation represents a core domain modification rather than the more commonly studied N-terminal tail acetylations. While N-terminal histone acetylations (such as H4K5) are primarily associated with chromatin assembly during DNA replication , H4K79 acetylation appears to have specialized functions:

Histone ModificationLocationPrimary FunctionsDetection Method
H4K5 acetylationN-terminal tailNewly assembled chromatin, DNA replicationAnti-Acetyl H4K5 antibodies
H4K79 acetylationCore domainDNA damage response, telomeric silencingAnti-Acetyl-HIST1H4A (K79) antibodies
H4K91 acetylationCore domainChromatin assembly, silent chromatin regulationAnti-Acetyl H4K91 antibodies

This core domain acetylation at K79 functions in concert with, but distinctly from, other histone modifications like H3K79 methylation to regulate chromatin states .

What are the optimal protocols for using Acetyl-HIST1H4A (K79) Antibody in ChIP experiments?

When performing ChIP with Acetyl-HIST1H4A (K79) Antibody, researchers should consider these methodological optimizations:

  • Cross-linking: Use 1% formaldehyde for 10 minutes at room temperature for optimal chromatin preparation

  • Sonication: Adjust sonication conditions to obtain chromatin fragments between 200-500bp

  • Antibody specificity control: Perform parallel immunoprecipitation with pre-immune serum as a negative control

  • Epitope masking prevention: Pre-incubate the antibody with lysate from H4K79A mutant cells to block potential cross-reactivity with other histone modifications

  • Validation strategy: Compare enrichment patterns between acetylated (active) and non-acetylated (silenced) genomic regions using qPCR before proceeding to genome-wide analysis

Research shows that H4K79 acetylation is significantly enriched in transcriptionally active regions of the genome and present at lower levels at telomeres and silenced loci like the HMR locus . This distribution pattern can serve as an internal validation of ChIP efficacy.

How does H4K79 acetylation functionally interact with the DNA damage response pathway?

H4K79 acetylation appears to play critical roles in DNA damage response that are independent of but complementary to other histone modifications:

  • Checkpoint response independence: Studies with H4K79A mutants reveal sensitivity to DNA-damaging agents that is distinct from defects in MEC1 or MEC3 kinase-dependent checkpoint responses

  • Repair pathway interactions: H4K79A mutations increase DNA damage sensitivity in both non-homologous end-joining (NHEJ) pathway (Δyku70) and recombinational repair (Δrad52) mutants, suggesting it does not function directly in either repair mechanism

  • Chromatin assembly connection: H4K79A mutants show epistatic interactions with mutations in chromatin assembly factors like ASF1, suggesting a role in post-damage chromatin restoration

  • Synergistic effects: Double mutants of H3K79A and H4K91A display increased sensitivity to DNA double-strand breaks compared to either single mutant, indicating that these modifications function in separate pathways during DNA damage repair

These findings suggest that researchers should consider H4K79 acetylation as a critical component when studying chromatin dynamics during DNA damage and repair processes.

What is the relationship between H4K79 acetylation and H3K79 methylation in epigenetic regulation?

The relationship between H4K79 acetylation and H3K79 methylation reveals complex crosstalk in chromatin regulation:

  • Silent chromatin effects: Both H4K79A and H3K79A mutations cause similar defects in silencing at telomeres and the HMR locus, suggesting they operate in a common pathway for maintaining silent chromatin structure

  • Reciprocal regulation: H4K79A mutations alter the distribution of H3K79 methylation at telomeres, while H3K79A mutations increase H4K79 acetylation at silenced loci, demonstrating bidirectional influence

  • Locus-specific dominance: At the HML locus, H3K79A has a more pronounced effect on silencing than H4K79A, but in double mutants, the H4K91A phenotype is dominant

  • Functional independence in DNA repair: Unlike their cooperative roles in silent chromatin, H3K79 methylation and H4K79 acetylation function independently in DNA damage repair, as evidenced by the increased sensitivity of double mutants

This interplay has significant implications for experimental design when studying either modification, as manipulating one can affect the other's distribution and function.

How can non-specific binding be minimized when using Acetyl-HIST1H4A (K79) Antibody?

To maximize specificity and reduce background when working with Acetyl-HIST1H4A (K79) Antibody:

  • Antibody pre-adsorption: Pre-incubate the antibody with lysate from cells containing the H4K79A allele to block potential cross-reactivity with other histone modifications

  • Blocking optimization: Use 5% BSA rather than milk-based blocking solutions, as milk contains bioactive compounds that may interfere with histone antibody binding

  • Validation controls: Always run parallel experiments with:

    • Unmodified recombinant H4 (negative control)

    • Acetylated H4 from HeLa cells (positive control)

  • Peptide competition: Use synthetic peptides with acetylated K79 as competitive binding controls to demonstrate specificity

  • Dot blot verification: Perform dot blot analysis with modified and unmodified peptides encompassing several sites of H4 acetylation to confirm antibody specificity before proceeding to complex samples

These approaches significantly enhance detection specificity, particularly in complex chromatin environments where multiple histone modifications coexist.

What techniques can distinguish newly deposited H4K79 acetylation from preexisting modifications?

Differentiating newly deposited H4K79 acetylation from established modifications requires temporal resolution techniques:

  • Pulse-chase labeling: Use methods similar to those employed for H4 acetylation studies, where newly replicated chromatin is labeled with [³H]thymidine in the presence of deacetylase inhibitors like sodium butyrate

  • Immunoprecipitation enrichment: Compare bound and unbound fractions after antibody immunoprecipitation to assess enrichment of newly synthesized DNA and associated histones

  • Deacetylase inhibition control: Include parallel experiments with and without deacetylase inhibitors to distinguish between newly deposited (acetylated) and mature (potentially deacetylated) chromatin

  • Replication inhibition studies: Analyze histone deposition during DNA replication inhibition to identify acetylation patterns associated with replication-independent histone exchange

  • Cytosolic extract analysis: Examine preassembly complexes in cytosolic extracts to detect newly synthesized H4 with K79 acetylation prior to chromatin incorporation

These approaches allow researchers to track the dynamics of H4K79 acetylation during chromatin assembly and remodeling processes.

How does the distribution of H4K79 acetylation compare with other histone modifications across the genome?

Genome-wide distribution of H4K79 acetylation follows distinct patterns that can be compared with other histone modifications:

  • Active vs. silenced regions: H4K79 acetylation is significantly enriched in transcriptionally active genomic regions while present at low levels at telomeres and silenced loci such as the HMR locus

  • Correlation with H3K79 methylation: H4K79 acetylation and H3K79 methylation show inverse correlation at silenced loci, with mutations in either causing redistribution of the other

  • Relationship to H4 N-terminal acetylation: H4K79 acetylation patterns differ from N-terminal tail acetylation, with tail acetylation increasing at telomeres and HMR in H4K79A mutants

  • Complementary analysis techniques:

    • ChIP-seq for genome-wide profiling

    • ChIP-qPCR for targeted locus validation

    • Western blotting for global level assessment

When designing experiments to map H4K79 acetylation, researchers should consider these distribution patterns and include appropriate controls for other modifications to accurately interpret results.

What are the implications of H4K79 acetylation for understanding disease mechanisms?

H4K79 acetylation research has potential implications for understanding disease mechanisms, particularly in:

  • Cancer epigenetics: Altered histone modification patterns, including core domain acetylations, are frequent in cancer cells and may contribute to oncogenic gene expression patterns

  • DNA repair disorders: Given the role of H4K79 acetylation in DNA damage responses, alterations may contribute to genomic instability in conditions like Fanconi anemia or ataxia telangiectasia

  • Silencing-related disorders: Since H4K79 acetylation affects telomeric silencing and heterochromatin maintenance, its dysregulation might contribute to diseases involving inappropriate gene silencing

  • Experimental approaches for disease research:

    • Compare H4K79 acetylation patterns between normal and disease tissues

    • Assess correlations between H4K79 acetylation alterations and disease progression

    • Investigate pharmacological agents that modulate H4K79 acetylation as potential therapeutic approaches

Research into these connections requires careful experimental design that accounts for the complex interplay between multiple histone modifications.

What emerging technologies might enhance the study of H4K79 acetylation?

Several cutting-edge technologies show promise for advancing H4K79 acetylation research:

  • CUT&RUN and CUT&Tag: These techniques offer higher resolution and lower background than traditional ChIP, potentially improving detection of H4K79 acetylation at specific genomic loci

  • Single-cell epigenomics: Emerging methods for single-cell histone modification profiling could reveal cell-to-cell variability in H4K79 acetylation patterns

  • Live-cell imaging: Development of acetylation-specific intrabodies or FRET-based sensors could enable real-time visualization of H4K79 acetylation dynamics

  • Mass spectrometry advances: Improved sensitivity in MS-based approaches may allow quantitative assessment of H4K79 acetylation co-occurrence with other modifications on the same histone tail

  • CRISPR-based epigenome editing: Targeted modification of H4K79 acetylation at specific loci using catalytically active or inactive histone acetyltransferases fused to Cas proteins

These technologies will likely permit more precise spatial and temporal resolution of H4K79 acetylation dynamics in diverse biological contexts.

What are the key unanswered questions regarding the enzymes that regulate H4K79 acetylation?

Critical gaps remain in our understanding of the enzymatic regulation of H4K79 acetylation:

  • Acetyltransferase identification: Unlike N-terminal tail acetylation by HAT1 and other known HATs, the specific enzyme(s) responsible for H4K79 acetylation remain elusive

  • Deacetylase specificity: Which histone deacetylases (HDACs) specifically target H4K79 acetylation, and how is their activity regulated?

  • Crosstalk regulation: How do enzymes that modify H4K79 and H3K79 communicate to maintain proper chromatin states?

  • Experimental approaches:

    • Systematic CRISPR screening of HATs and HDACs

    • In vitro acetylation assays with candidate enzymes

    • Proteomic identification of proteins specifically binding to acetylated H4K79

    • Structure-function analysis of putative H4K79-modifying enzymes

Addressing these questions will provide crucial insights into the regulatory mechanisms controlling this important histone modification.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.